Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

- 1. (Currently amended) A pharmaceutical composition for the inhibition of tumorigenesis comprising a pharmaceutical carrier and an antisense nucleic acid comprising at least 100 nucleotides hybridizable in a cell to at least a portion of an RNA transcript of a Nr-CAM gene of SEQ ID NO: 1 in an amount effective to inhibit tumorigenesis by inhibiting hyperproliferation of a human tumor cell having high Nr-CAM expression, wherein said composition is formulated for pharmaceutical use in humans.
 - 2. (Canceled)
- 3. (Currently amended) A method of inhibiting proliferation of a human tumor cell overexpressing Nr-CAM in a subject comprising administering locally to the subject, at the site or former site of the tumor, an effective amount of a Nr-CAM antisense nucleic acid comprising the complement of nucleotides 119 to 1434 of SEQ ID NO.: 1; wherein the tumor cell comprises a glioblastoma, a glioma, an astrocytoma, or an oligodendroglioma, and wherein the Nr-CAM antisense nucleic acid is administered in an amount effective to inhibit tumorigenesis by inhibiting proliferation of a human tumor cell having high Nr-CAM expression.
 - 4. (Canceled)
 - 5. (Canceled)
- 6. (Original) The method according to claim 3 in which the subject is a human.
 - 7. (Canceled)

- 8. (Previously presented) The method according to claim 3 in which the glioblastoma is glioblastoma multiforme.
 - 9-21. (Canceled)
- 22. (Previously presented) The composition of claim 1, wherein the composition is formulated as a liquid.
 - 23. (Canceled)
- 24. (Previously presented) The method of claim 3, wherein the local administration is by direct injection.
- 25. (Previously presented) The method of claim 24, wherein the Nr-CAM antisense nucleic acid is administered locally by direct injection at the site or former site of the tumor.
- 26. (Previously presented) The method of claim 25, wherein the administration is intratumoral.

27-33. (Canceled)

- 34. (Previously presented) The composition of claim 1, wherein the antisense nucleic acid comprises the complement of nucleotides 119 to 1434 of SEQ ID NO: 1.
- 35. (Previously presented) The composition of claim 1, wherein the antisense nucleic acid comprises the complement of nucleotides 1410 to 2746 of SEQ ID NO: 1.